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90% 8,300/9,500 1,300/1,400 6,6/6,9 The first value in the rows incremental costs and LYG, and ICER indicates a scenario in which patients with ER+/HER2-receptor status were treated with Anastrozole and ER-/HER2+ patients were treated with Trastuzumab monotherapy, while the second value indicates a scenario in which ER+/HER2-patients were treated with Letrozole and ER-/HER2+ patients were treated with Trastuzumab combination therapy (trastuzumab and paclitaxel). The first value in the rows incremental costs and LYG, and ICER indicates a scenario in which patients with ER+/HER2-receptor status were treated with Anastrozole and ER-/HER2+ patients were treated with Trastuzumab monotherapy, while the second value indicates a scenario in which ER+/ HER2-patients were treated with Letrozole and ER-/HER2+ patients were treated with Trastuzumab combination therapy (trastuzumab and paclitaxel)
We found the costs per tablet or milligram of the relevant therapies in the Netherlands (ZIN, 2017) , and estimated the costs per package and vial. We obtained the prices for the same therapies in the UK from the National Formulary [32] [33] [34] [35] [36] [37] [38] . Then, we compared the Dutch prices [31, 40, 41] to the prices of the same therapies in the United Kingdom [32] [33] [34] [35] [36] [37] [38] . Table A shows the differences in prices for the used therapies between the Netherlands and the UK. Apparently, prices per package/vial were lower in the Netherlands for some therapies and higher for trastuzumab and docetaxel, however, the World Data Bank [39] have reported that treatment expenses amounted to €5,169 in the Netherlands versus €3,572 in the UK [39] . Therefore, in order not to underestimate costseffectiveness evaluations we chose to use the UK prices, converted to euros according to the 2016 exchange rate and corrected for the difference in per capita expenses between the United Kingdom and the Netherlands using World data bank estimates from 2015 [39] .
The cost of the trastuzumab monotherapy included the course of treatment with trastuzumab administered over a period of 12 weeks. The cost of trastuzumab combination therapy included the costs of the two therapies, anti-HER2-agent trastuzumab and chemotherapy with paclitaxel, administered over a period of 38 weeks. The cost of combination therapy with trastuzumab and anastrozole included the costs of the two treatments for a patient with an average weight of 67 kg, administered over a mean treatment period of 15 months and excluding administration, monitoring and wastage costs. Thus, the acquisition cost for a lifetime of treatment with trastuzumab plus anastrozole was estimated as the mean cost of a weekly and a 3-weekly schedule of treatment. The cost of treatment with the chemotherapy agent docetaxel was based on the cost per patient for six cycles of treatment. The acquisition cost of anastrozole was based on the cost per package of 28 tablets/1-mg each administered over a period of 15 months. The acquisition cost of letrozole was based on the cost per package of 28 tablets/2.5-mg administered over a period of 15 months. All costs of different treatments were estimated per patient. 
